Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 686-690, 2003; 10.1373/49.4.686
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (37)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, E. S.
Right arrow Articles by Mannino, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, E. S.
Right arrow Articles by Mannino, D. M.
Related Collections
Right arrow Pediatric Clinical Chemistry
Right arrow Nutrition
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:686-690.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Population Distribution of High-Sensitivity C-reactive Protein among US Men: Findings from National Health and Nutrition Examination Survey 1999–2000

Earl S. Ford1,a, Wayne H. Giles2, Gary L. Myers3 and David M. Mannino1

Divisions of
1 Environmental Hazards and Health Effects and
3 Laboratory Sciences, National Center for Environmental Health, and
2 Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341

aaddress correspondence to this author at: Centers for Disease Control and Prevention, 4770 Buford Hwy., MS K66, Atlanta, GA 30341; fax 770-488-8150, e-mail esf2@cdc.gov

The first 300 words of the full text of this article appear below.

C-reactive protein, an acute-phase reactant, is produced in the liver and belongs to the pentraxin family of proteins (1). This protein is very sensitive to inflammation, and its concentration can increase rapidly in response to a wide range of stimuli. Originally described in 1930 (2), C-reactive protein measurements served mostly in a diagnostic, albeit a nonspecific one, and in a monitoring role in such fields as infectious diseases and rheumatology. In the past decade, as the role of inflammation in cardiovascular disease became appreciated, interest turned to C-reactive protein as a possible risk marker for cardiovascular disease. Since then, studies have shown that the C-reactive protein concentration is positively associated with cardiovascular disease incidence and mortality (3) even when the concentration is <3.0 mg/L, which was previously thought to be "normal" (4).

As these research findings have reached the medical community, the use of C-reactive protein measurements has increased, but guidelines addressing the role of C-reactive protein testing in the primary and secondary prevention of cardiovascular disease have not been developed. To facilitate the development of such guidelines, several issues must be addressed, including population distributions of C-reactive protein concentrations and thresholds for interventions.

A key piece of missing information has been the population distribution of C-reactive protein in the US, especially the distribution of C-reactive protein concentrations <3.0 mg/L. This information is helpful in calculating the fraction of cardiovascular disease attributable to increased C-reactive protein concentrations. The National Health and Nutrition Examination Survey (NHANES) III provided information only on the upper ranges of the C-reactive protein distribution (5)(6) because the C-reactive protein test used in that survey had a lower detection limit of 3.0 mg/L.

Another missing piece of information is whether Creactive protein concentration distributions differ . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Cushman, L. A. McClure, V. J. Howard, N. S. Jenny, S. G. Lakoski, and G. Howard
Implications of Increased C-Reactive Protein for Cardiovascular Risk Stratification in Black and White Men and Women in the US
Clin. Chem., September 1, 2009; 55(9): 1627 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
S-S. Lee, S. Singh, L. Magder, and M. Petri
Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus
Lupus, February 1, 2008; 17(2): 114 - 123.
[Abstract] [PDF]

Home page
 StrokeHome page
J. Ishikawa, Y. Tamura, S. Hoshide, K. Eguchi, S. Ishikawa, K. Shimada, and K. Kario
Low-Grade Inflammation Is a Risk Factor for Clinical Stroke Events in Addition to Silent Cerebral Infarcts in Japanese Older Hypertensives: The Jichi Medical School ABPM Study, Wave 1
Stroke, March 1, 2007; 38(3): 911 - 917.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. C. Crawford, C. L. Sanders, X. Qin, J. D. Smith, C. Shephard, M. Wong, L. Witrak, M. J. Rieder, and D. A. Nickerson
Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey
Circulation, December 5, 2006; 114(23): 2458 - 2465.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. E. Laaksonen, L. Niskanen, K. Nyyssonen, K. Punnonen, T.-P. Tuomainen, and J. T. Salonen
C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study
Eur. Heart J., September 1, 2005; 26(17): 1783 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Khera, D. K. McGuire, S. A. Murphy, H. G. Stanek, S. R. Das, W. Vongpatanasin, F. H. Wians Jr, S. M. Grundy, and J. A. de Lemos
Race and Gender Differences in C-Reactive Protein Levels
J. Am. Coll. Cardiol., August 2, 2005; 46(3): 464 - 469.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al.
Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members
Stroke, June 1, 2005; 36(6): 1316 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
B. J. Nicklas, T. You, and M. Pahor
Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training
Can. Med. Assoc. J., April 26, 2005; 172(9): 1199 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al.
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group
Circulation, December 21, 2004; 110(25): e545 - e549.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. S. Ford, W. H. Giles, A. H. Mokdad, and G. L. Myers
Distribution and Correlates of C-Reactive Protein Concentrations among Adult US Women
Clin. Chem., March 1, 2004; 50(3): 574 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. B. Ledue and N. Rifai
Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment
Clin. Chem., August 1, 2003; 49(8): 1258 - 1271.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.